LON:AVCT - Avacta Group Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
GBX 42.25 -1.05 (-2.42 %)
(As of 02/20/2019 09:26 AM ET)
Previous CloseGBX 43.30
Today's RangeGBX 42.25 - GBX 43.20
52-Week RangeGBX 40 - GBX 98
Volume46,127 shs
Average Volume19,964 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Avacta Group Plc offers reagents and therapeutics based on Affimer technology for diagnostic and research applications in the United Kingdom. It operates through two segments, Life Sciences and Animal Health. The company's custom Affimer products are also used in drugs and biomarkers discovery in biotech research and development. In addition, it provides tools and contract services to assist the diagnosis of conditions in animals to enable treatment for veterinarians. The company has a collaboration, licensing, and option agreement with Moderna Therapeutics; research collaboration with OncoSec Medical Incorporated for gene delivery of therapeutic Affimers; and a co-development partnership agreement with Bach Biosciences LLP to develop Affimer drug conjugate therapies. Avacta Group Plc was incorporated in 2003 and is based in Wetherby, the United Kingdom.

Receive AVCT News and Ratings via Email

Sign-up to receive the latest news and ratings for AVCT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medical Devices



Sales & Book Value

Annual SalesN/A



OptionableNot Optionable

Avacta Group (LON:AVCT) Frequently Asked Questions

What is Avacta Group's stock symbol?

Avacta Group trades on the London Stock Exchange (LON) under the ticker symbol "AVCT."

What price target have analysts set for AVCT?

0 equities research analysts have issued 12 month price objectives for Avacta Group's stock. Their predictions range from GBX 200 to GBX 200. On average, they anticipate Avacta Group's stock price to reach GBX 200 in the next year. This suggests a possible upside of 373.4% from the stock's current price. View Analyst Price Targets for Avacta Group.

Has Avacta Group been receiving favorable news coverage?

Media headlines about AVCT stock have been trending somewhat positive this week, InfoTrie reports. InfoTrie ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Avacta Group earned a news sentiment score of 1.4 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 4.0 out of 10, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.

Who are some of Avacta Group's key competitors?

Who are Avacta Group's key executives?

Avacta Group's management team includes the folowing people:
  • Prof. Alastair Smith, CEO & Exec. Director
  • Mr. Tony Gardiner, CFO, Company Sec. & Exec. Director (Age 48)
  • Dr. Michael Albin, Adviser
  • Dr. Matt Johnson, Chief Technology Officer
  • Dr. Amrik Basran Ph.D., Chief Scientific Officer

How do I buy shares of Avacta Group?

Shares of AVCT and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Avacta Group's stock price today?

One share of AVCT stock can currently be purchased for approximately GBX 42.25.

What is Avacta Group's official website?

The official website for Avacta Group is https://www.avacta.com/key-information.

How can I contact Avacta Group?

Avacta Group's mailing address is Unit 20, Ash Way, WETHERBY, LS23 7FA, United Kingdom. The biotechnology company can be reached via phone at +44-1904-217070.

MarketBeat Community Rating for Avacta Group (LON AVCT)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  192 (Vote Outperform)
Underperform Votes:  174 (Vote Underperform)
Total Votes:  366
MarketBeat's community ratings are surveys of what our community members think about Avacta Group and other stocks. Vote "Outperform" if you believe AVCT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AVCT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/20/2019 by MarketBeat.com Staff

Featured Article: What is a balanced fund?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel